L-citrulline for blood flow: does it actually work?
Yes, for the narrow thing it was measured on — and the dose on most labels is too low to reproduce it.
- L-citrulline raises plasma arginine more reliably than arginine itself does.
- Blood-flow and exercise-performance effects are consistent at 6–8 g per day.
- Most commercial pre-workouts contain 1–3 g, often as citrulline malate, where half the weight is malate.
- It is not a blood-pressure treatment. Effects on resting BP are small and inconsistent.
What the trials measured
Almost all of the positive research measures one of two things: flow-mediated dilation, a direct ultrasound measure of how much an artery widens, or performance on a repeated-effort exercise test. Both improved against placebo in the majority of controlled trials at 6 g or more per day, taken for at least seven days. Single-dose studies are much weaker — the effect appears to need accumulation.
The mechanism is well characterised, which is part of why we grade this strong: citrulline bypasses the intestinal and hepatic breakdown that limits oral arginine, so it raises circulating arginine — the substrate for nitric oxide — more effectively than arginine supplements do.
Where the label trips people up
"Citrulline malate 2:1" means two parts citrulline to one part malate, so 6 g of citrulline malate delivers about 4 g of citrulline. A product listing "1.5 g citrulline malate" is delivering roughly a sixth of the studied dose. This is the single most common reason someone tries citrulline and concludes it does nothing.
What we'd do
Buy plain L-citrulline rather than a blend, take 6 g daily for two weeks before judging it, and ignore any claim about heart health — the evidence supports arterial dilation and exercise performance, not cardiovascular outcomes. If you want the outcome to be lower blood pressure, the interventions with real outcome data are sodium, weight, exercise and medication.
Limits of this review
Most trials ran 7–21 days in healthy, trained adults under 40. We found no long-term safety data past 12 weeks, and very little in older adults or people with existing vascular disease — the group most interested in "blood flow" claims.
Reviewed by our editorial team on 15 May 2026. Corrections are published at the bottom of the page with the date — tell us if something here is wrong.